ASH 2021

Part II: CAR-T cells - all over the field data for DLBCL

Part I: Pola-R-CHP - possible new standard in 1st line?

axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R DLBCL

pola-R-CHP vs. R-CHOP: a new standard?

Axi-cel - new standard for r/r LBCL patients?

Tisa-cel - new CAR-T option for R/R aNHL

Prevention of CNS relapse after R-CHOP

HD-MTX does not lower SCNS rates in high-risk patients

La prevenzione della recidiva a carico del sistema nervoso Centrale nel DLBCL

Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen beim r/r DLBCL

Axi Cel: un nuovo standard nel DLBCL recidivato o refrattario

pola-R-CHP vs. R-CHOP: Neuer Standard?

Part II: The white elephant in the room - BTKi

Part I: Potential change in first-line treatment?

Encouraging real world safety and efficacy data of brexu-cel in R/R MCL in a population outside of ZUMA-2

Next generation BTKI Pirtobrutinib

Maintenance with Rituximab-Lenalidomid (R2)

Pirtobrutinib shows promising efficacy and safety in heavily pretreated patients with MCL, including those previously treated with BTKi

Focus on maintenance is critical in MCL

Pirtobrutinib - promising agent moving forward

Low-dose lenalidomide added to rituximab maintenance in older patients with MCL prolongs PFS, but not OS

Glofitamab SUD as monotherapy after Gpt induced high response rates

HiDAC-containing induction before ASCT substantially prolongs TTF and PFS in younger patients with MCL - Final results of the MCL YOUNGER trial

Pirtobrutinib es eficaz y seguro en pacientes muy pretratados con LCM, incluyendo pacientes que habían fracasado a iBTK

Ruolo del mantenimento con R2 nel linfoma mantellare

Eficacia y seguridad de brexu-cel en pacientes con LCM r/r de la vida real

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

La inducción con citarabina a dosis altas antes del transplante autólogo en pacientes jóvenes con LCM prolonga significativamente el TFT y la SLP - Resultados finales del estudio MCL YOUNGER

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Añadir lenalidomida a dosis bajas a rituximab en el mantenimiento de pacientes mayores con LCM prolonga la SLP, pero no la SG

Part II: Bi-specific antibodies as an attractive agent

Part I: CAR-T cells on the way

First-line options and RM

MRD monitoring in follicular lymphoma is extremely valuable

Novel immunotherapy approaches to R/R follicular lymphoma

Active new therapy for 3L+ R/R FL

Mosunetuzumab + Lenalidomid beim r/r FL

Rituximab-Erhaltung nach ICT bleibt Standard

Ruolo del monitoraggio della malattia minima residua nel linfoma follicolare

Part II: More data to wait for

Part I: Promising data in CLL

BTKi as new option for untreated CLL/SLL patients

Pirtobrutinib - promising efficacy in heavily pretreated CLL/SLL patients

The immunotherapy tsunami continues - bispecific antibodies

Big data on smoldering multiple myeloma: the iStopMM trial

The immunotherapy tsunami continues - CAR-T cells

NDMM: On the way to cure?

The future is already here - the use of antibodies in newly diagnosed patients

Quadruple therapy - the treatment of choice in NDMM

No benefit for elotuzumab in NDMM

PFS separation in the Griffin trial

Triplet therapie in elderly patients

Positive results for high-risk myeloma from the UK

Quadruple regimens for NDMM

The future is already here - the use of antibodies in newly diagnosed patients

PFS separation in the Griffin trial

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei NDMM

Isatuximab + RVd erfogreich, Elotuzumab nicht

New bispecific antibodies and CAR-T cells for RRMM patients

talquetamab & cevostamab: bispecific antibodies beyond BCMA

Personalized medicine with venetoclax

TAK-573 - a really new mechanism of treatment in multiple myeloma

Not another BCMA drug

Is CAR-T cell treatment better in heavly pretreated patients?

KRd consolidation reverses PET positivity in 1/3 of the patients

Update on bispecific antibody teclistamab

cilta-cel highly effective in heavily pretreated patients

cilta-cel: early, deep and durable responses in heavily pretreated patients

Elranatamab - a new bispecific antibody in RRMM

cilta-cel hoch erfolgreich bei stark vorbehandelten Patienten

New bispecific antibodies and CAR-T cells for RRMM patients

TAK-573 - a really new mechanism of treatment in multiple myeloma

KRd consolidation reverses PET-positivity in 1/3 of the patients

Talquetamab und Cevostamab: Neue bispezifische Ak jenseits von BCMA

Bispezifischer Antikörper Teclistamab beim r/r MM

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen beim r/r MM

CAR-T oder bispezifische MoAk in der Rezidivtherapie - oder beides?

Myeloma precursor disease 2021

MGUS and COVID-19 risk

New reference values for light chains in multiple myeloma associated with renal failure

New reference values for light chains in multiple myeloma associated with renal failure

Prävalenz und Risikostratifikation beim SMM

Myeloma precurser disease 2021